ical ▁tri als ▁included : ▁L Y 2 8 0 1 6 5 3 , ▁am uv atin ib ▁( MP - 4 7 0 ), ▁bos ut in ib ▁( SK I - 6 0 6 ), ▁M G CD ▁ 2 6 5 , ▁ASP 2 2 1 5 , ▁cab oz antin ib ▁( X L 1 8 4 ), ▁for et in ib ▁( GS K 1 3 6 3 0 8 9 / X L 8 8 0 ), ▁and ▁S G I - 7 0 7 9 . ▁ ▁A stell as ▁Ph arma ▁is ▁currently ▁testing ▁g il ter it in ib ▁( AS P 2 2 1 5 ), ▁a ▁dual ▁F LT 3 - AX L ▁ty ros ine ▁kin ase ▁in hib itor ▁in ▁ac ute ▁my el oid ▁le uk emia ▁( AML ). ▁In ▁ 2 0 1 7 , ▁g il ter it in ib ▁gained ▁F DA ▁or phan ▁drug ▁status ▁for ▁A ML . ▁ ▁These ▁approved ▁dru gs ▁and ▁on going ▁and ▁pending ▁clin ical ▁tri als ▁highlight ▁the ▁potentially ▁wide - r anging ▁safety ▁and ▁effic acy ▁of ▁A X L ▁in hib ition . ▁ ▁Inter actions ▁▁ ▁A X L ▁re ceptor ▁ty ros ine ▁kin ase ▁has ▁been ▁shown ▁to ▁interact ▁with ▁T EN C 1 . ▁ ▁References ▁ ▁Further ▁reading ▁ ▁External ▁links ▁▁▁▁▁ ▁Category : Ty ros ine ▁kin ase ▁re cept ors <0x0A> </s> ▁Gary ▁Steven ▁Wilson ▁( born